For instance, concomitant TP53 mutations in NSCLC activate the aforementioned intracellular pathways that involve EGFR translocation and also worsen the KRAS-driven oncogenic properties [11]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.